Equities research analysts expect Albireo Pharma Inc (NASDAQ:ALBO) to announce sales of $1.65 million for the current quarter, Zacks reports. Four analysts have provided estimates for Albireo Pharma’s earnings, with the lowest sales estimate coming in at $850,000.00 and the highest estimate coming in at $3.00 million. Albireo Pharma reported sales of $11.20 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 85.3%. The firm is scheduled to announce its next earnings results on Thursday, May 16th.
According to Zacks, analysts expect that Albireo Pharma will report full year sales of $9.09 million for the current fiscal year, with estimates ranging from $4.85 million to $20.00 million. For the next financial year, analysts anticipate that the business will report sales of $24.05 million, with estimates ranging from $5.34 million to $42.57 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.18). The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.94 million. Albireo Pharma had a negative net margin of 361.94% and a negative return on equity of 32.42%.
A number of analysts recently commented on the company. ValuEngine upgraded Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. BidaskClub upgraded Albireo Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. Zacks Investment Research cut Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, March 11th. Wedbush set a $69.00 price target on Albireo Pharma and gave the stock a “buy” rating in a research report on Sunday, March 10th. Finally, HC Wainwright started coverage on Albireo Pharma in a research report on Thursday, February 28th. They issued a “buy” rating and a $62.00 price target for the company. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Albireo Pharma currently has a consensus rating of “Buy” and a consensus target price of $53.40.
Albireo Pharma stock opened at $34.59 on Friday. The firm has a market cap of $416.12 million, a P/E ratio of -8.78 and a beta of 1.72. Albireo Pharma has a one year low of $19.10 and a one year high of $37.95.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Alps Advisors Inc. boosted its stake in shares of Albireo Pharma by 30.6% in the fourth quarter. Alps Advisors Inc. now owns 27,659 shares of the biopharmaceutical company’s stock worth $678,000 after acquiring an additional 6,478 shares during the period. BlackRock Inc. boosted its stake in shares of Albireo Pharma by 11.4% in the third quarter. BlackRock Inc. now owns 584,177 shares of the biopharmaceutical company’s stock worth $19,255,000 after acquiring an additional 59,901 shares during the period. Fosun International Ltd bought a new position in shares of Albireo Pharma in the fourth quarter worth about $4,492,000. Bank of New York Mellon Corp boosted its stake in shares of Albireo Pharma by 8.6% in the third quarter. Bank of New York Mellon Corp now owns 35,023 shares of the biopharmaceutical company’s stock worth $1,154,000 after acquiring an additional 2,760 shares during the period. Finally, Sectoral Asset Management Inc boosted its stake in shares of Albireo Pharma by 21.3% in the fourth quarter. Sectoral Asset Management Inc now owns 229,978 shares of the biopharmaceutical company’s stock worth $5,641,000 after acquiring an additional 40,400 shares during the period. Institutional investors and hedge funds own 66.85% of the company’s stock.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Featured Story: What type of investment options does a Roth IRA provide?
Get a free copy of the Zacks research report on Albireo Pharma (ALBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.